Literature DB >> 22767263

Underlying steatohepatitis, but not simple hepatic steatosis, increases morbidity after liver resection: a case-control study.

Srinevas K Reddy1, J Wallis Marsh, Patrick R Varley, Brady K Mock, Kapil B Chopra, David A Geller, Allan Tsung.   

Abstract

UNLABELLED: Despite the high prevalence of fatty liver disease, the safety of liver resection in settings of steatohepatitis (SH) or hepatic steatosis is poorly understood. The aim of this study was to determine whether underlying SH or simple hepatic steatosis increases morbidity after liver resection. We compared patients undergoing liver resection with underlying SH or greater than 33% simple hepatic steatosis to controls selected for similar demographics, diagnoses, comorbidities, preoperative chemotherapy treatments, and extent of partial hepatectomy. Primary endpoints included postoperative overall and hepatic-related morbidity. One hundred and two patients with SH and 72 with greater than 33% simple hepatic steatosis who underwent liver resection from 2000 to 2011 were compared to corresponding controls. There were no differences in extent or approach of liver resection, malignant indications, preoperative chemotherapy treatment, elements of metabolic syndrome, alcohol use history, American Society of Anesthesiologists score, age, or gender between patients with SH or simple steatosis and corresponding controls. Ninety-day postoperative overall morbidity (56.9% versus 37.3%; P = 0.008), any hepatic-related morbidity (28.4% versus 15.7%; P = 0.043), surgical hepatic complications (19.6% versus 8.8%; P = 0.046), and hepatic decompensation (16.7% versus 6.9%; P = 0.049) were greater among SH patients, compared to corresponding controls. In contrast, there were no differences in postoperative overall morbidity (34.7% versus 44.4%; P = 0.310), any hepatic-related morbidity (19.4% versus 19.4%; P = 1.000), surgical hepatic complications (13.9% versus 9.7%; P = 0.606), or hepatic decompensation (8.3% versus 9.7%; P = 0.778) between simple hepatic steatosis patients and corresponding controls. Using multivariable logistic regression, SH was independently associated with postoperative overall (odds ratio [OR], 2.316; 95% confidence interval [95% CI]: 1.267-4.241; P = 0.007) and any hepatic-related (OR, 2.722; 95% CI: 1.201-6.168; P = 0.016) morbidity.
CONCLUSION: Underlying SH, but not simple hepatic steatosis, increases overall and hepatic-related morbidity after liver resection.
Copyright © 2012 American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Year:  2012        PMID: 22767263     DOI: 10.1002/hep.25935

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  32 in total

1.  Impact of Metabolic Syndrome on Postoperative Outcomes Among Medicare Beneficiaries Undergoing Hepatectomy.

Authors:  Alessandro Paro; Diamantis I Tsilimigras; Djhenne Dalmacy; Rayyan S Mirdad; J Madison Hyer; Timothy M Pawlik
Journal:  J Gastrointest Surg       Date:  2021-02-05       Impact factor: 3.452

Review 2.  Defining Post Hepatectomy Liver Insufficiency: Where do We stand?

Authors:  Kelly Lafaro; Stefan Buettner; Hadia Maqsood; Doris Wagner; Fabio Bagante; Gaya Spolverato; Li Xu; Ihab Kamel; Timothy M Pawlik
Journal:  J Gastrointest Surg       Date:  2015-06-11       Impact factor: 3.452

3.  Long-term influence of chemotherapy on steatosis-associated advanced hepatic fibrosis.

Authors:  Srinevas K Reddy; Colleen Reilly; Min Zhan; Ayse L Mindikoglu; Yixing Jiang; Barton F Lane; H Richard Alexander; William J Culpepper; Samer S El-Kamary
Journal:  Med Oncol       Date:  2014-05-06       Impact factor: 3.064

Review 4.  Metabolic syndrome and non-alcoholic fatty liver disease in liver surgery: The new scourges?

Authors:  François Cauchy; David Fuks; Alban Zarzavadjian Le Bian; Jacques Belghiti; Renato Costi
Journal:  World J Hepatol       Date:  2014-05-27

Review 5.  A review of current status of living donor liver transplantation.

Authors:  Gil-Chun Park; Gi-Won Song; Deok-Bog Moon; Sung-Gyu Lee
Journal:  Hepatobiliary Surg Nutr       Date:  2016-04       Impact factor: 7.293

6.  Minimally Invasive Resection of Colorectal Cancer Liver Metastases Leads to an Earlier Initiation of Chemotherapy Compared to Open Surgery.

Authors:  Samer Tohme; Julie Goswami; Katrina Han; Alexis P Chidi; David A Geller; Srinevas Reddy; Ana Gleisner; Allan Tsung
Journal:  J Gastrointest Surg       Date:  2015-10-05       Impact factor: 3.452

7.  Significance of the preoperative regional maximal removal rate of technetium-99m-galactosyl human serum albumin in the future remnant liver: a sequential study of regional maximal removal rate of technetium-99m-galactosyl human serum albumin in the whole liver.

Authors:  Yukinori Tanoue; Atsushi Nanashima; Koichi Yano; Yoshirou Fujii; Masahide Hiyoshi; Naoya Imamura; Takeomi Hamada; Makoto Ikenoue; Takashi Wada; Yoichi Mizutani; Toshinori Hirai
Journal:  Nucl Med Commun       Date:  2019-02       Impact factor: 1.690

Review 8.  Ischemia–reperfusion injury in patients with fatty liver and the clinical impact of steatotic liver on hepatic surgery.

Authors:  Hirotaka Tashiro; Shintaro Kuroda; Yoshihiro Mikuriya; Hideki Ohdan
Journal:  Surg Today       Date:  2014-09       Impact factor: 2.549

Review 9.  Reactive oxygen and nitrogen species in steatotic hepatocytes: a molecular perspective on the pathophysiology of ischemia-reperfusion injury in the fatty liver.

Authors:  Megan J Reiniers; Rowan F van Golen; Thomas M van Gulik; Michal Heger
Journal:  Antioxid Redox Signal       Date:  2014-02-19       Impact factor: 8.401

10.  Prevalence of nonalcoholic steatohepatitis among patients with resectable intrahepatic cholangiocarcinoma.

Authors:  Srinevas K Reddy; Omar Hyder; J Wallis Marsh; Georgios C Sotiropoulos; Andreas Paul; Sorin Alexandrescu; Hugo Marques; Carlo Pulitano; Eduardo Barroso; Luca Aldrighetti; David A Geller; Christine Sempoux; Vlad Herlea; Irinel Popescu; Robert Anders; Laura Rubbia-Brandt; Jean-Francois Gigot; Giles Mentha; Timothy M Pawlik
Journal:  J Gastrointest Surg       Date:  2013-01-25       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.